News on Aestus Pharmaceuticals Corp from BioPortfolio.com http://www.BioPortfolio.com Consolidated Aestus Pharmaceuticals Corp news from BioPortfolio.com Wed, 10 Feb 2010 14:03:29 GMT en PicksThatMove.com Announces Investment Opinion on Western Coal Corp., Arco Resources Corp., Rexahn Pharmaceuticals Inc, Cord Blood America Inc. and Cell Therapeutics Inc.http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038956&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038956&THISHREF=http://c.moreover.com/click/here.pl%3fz2537851146%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038956&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038956&THISHREF=http://c.moreover.com/click/here.pl%3fz2537851146%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposiumhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042043&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042043&THISHREF=http://c.moreover.com/click/here.pl%3fz2539292898%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042043&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042043&THISHREF=http://c.moreover.com/click/here.pl%3fz2539292898%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCNW Telbec: Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposiumhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042031&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042031&THISHREF=http://c.moreover.com/click/here.pl%3fz2539286391%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042031&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042031&THISHREF=http://c.moreover.com/click/here.pl%3fz2539286391%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCanada NewsWire: Activist Investor Pushes Celera to Divest Merck Bone Drug Royaltieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040410&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040410&THISHREF=http://c.moreover.com/click/here.pl%3fz2538725899%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040410&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040410&THISHREF=http://c.moreover.com/click/here.pl%3fz2538725899%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioWorld: Activist Investor Pushes Celera to Divest Merck Bone Drug Royaltieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039489&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039489&THISHREF=http://c.moreover.com/click/here.pl%3fz2538152182%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039489&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039489&THISHREF=http://c.moreover.com/click/here.pl%3fz2538152182%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposium / Forms European Subsidiary, Raptor Pharmaceuticals Europe BVhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042039&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042039&THISHREF=http://c.moreover.com/click/here.pl%3fz2539292574%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042039&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042039&THISHREF=http://c.moreover.com/click/here.pl%3fz2539292574%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFinanzNachrichten.de: Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposiumhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041945&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041945&THISHREF=http://c.moreover.com/click/here.pl%3fz2539260312%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041945&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041945&THISHREF=http://c.moreover.com/click/here.pl%3fz2539260312%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSys-Con Media: Genzyme, Isis report positive study on heart drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042090&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042090&THISHREF=http://c.moreover.com/click/here.pl%3fz2539311399%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042090&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042090&THISHREF=http://c.moreover.com/click/here.pl%3fz2539311399%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMarketWatch: Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042034&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042034&THISHREF=http://c.moreover.com/click/here.pl%3fz2539288477%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042034&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042034&THISHREF=http://c.moreover.com/click/here.pl%3fz2539288477%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041705&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041705&THISHREF=http://c.moreover.com/click/here.pl%3fz2539210806%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041705&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041705&THISHREF=http://c.moreover.com/click/here.pl%3fz2539210806%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStockwatch: Neuraltus Pharmaceuticals names new president and CEO - Zibb.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040164&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040164&THISHREF=http://c.moreover.com/click/here.pl%3fz2538621278%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040164&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040164&THISHREF=http://c.moreover.com/click/here.pl%3fz2538621278%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: IntelGenx Receives FDA Complete Response Letter CPI-300http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039356&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039356&THISHREF=http://c.moreover.com/click/here.pl%3fz2538056872%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039356&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039356&THISHREF=http://c.moreover.com/click/here.pl%3fz2538056872%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: Genzyme drug test meets primary end pointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042194&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042194&THISHREF=http://c.moreover.com/click/here.pl%3fz2539347182%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042194&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042194&THISHREF=http://c.moreover.com/click/here.pl%3fz2539347182%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Globe: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042180&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042180&THISHREF=http://c.moreover.com/click/here.pl%3fz2539342533%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042180&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042180&THISHREF=http://c.moreover.com/click/here.pl%3fz2539342533%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042169&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042169&THISHREF=http://c.moreover.com/click/here.pl%3fz2539340197%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042169&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Aestus%20Pharmaceuticals%20Corp&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042169&THISHREF=http://c.moreover.com/click/here.pl%3fz2539340197%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: